154 related articles for article (PubMed ID: 20972736)
1. Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients.
Chen LL; Liao YF; Zeng TS; Yu F; Li HQ; Feng Y
Endocrine; 2010 Oct; 38(2):266-75. PubMed ID: 20972736
[TBL] [Abstract][Full Text] [Related]
2. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
Erem C; Ozbas HM; Nuhoglu I; Deger O; Civan N; Ersoz HO
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):295-302. PubMed ID: 24710641
[TBL] [Abstract][Full Text] [Related]
3. Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes.
Chen LL; Yu F; Zeng TS; Liao YF; Li YM; Ding HC
Eur J Pharmacol; 2011 Jun; 659(2-3):296-301. PubMed ID: 21453695
[TBL] [Abstract][Full Text] [Related]
4. Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients.
Negro R; Greco EL; Greco G
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):215-219. PubMed ID: 29558784
[TBL] [Abstract][Full Text] [Related]
5. Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
Esposito K; Maiorino MI; Di Palo C; Gicchino M; Petrizzo M; Bellastella G; Saccomanno F; Giugliano D
Diabetes Obes Metab; 2011 May; 13(5):439-45. PubMed ID: 21255215
[TBL] [Abstract][Full Text] [Related]
6. Epidemiologic Surveillance of Glycemic Response to a Scored, Breakable, Extended Release, Fixed Dose Combination of Gliclazide and Metformin in Persons with Type 2 Diabetes.
Kalra S; Das AK
J Assoc Physicians India; 2017 Jun; 65(6):38-41. PubMed ID: 28782312
[TBL] [Abstract][Full Text] [Related]
7. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
Fadini GP; Boscaro E; Albiero M; Menegazzo L; Frison V; de Kreutzenberg S; Agostini C; Tiengo A; Avogaro A
Diabetes Care; 2010 Jul; 33(7):1607-9. PubMed ID: 20357375
[TBL] [Abstract][Full Text] [Related]
8. Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study.
Ahmed FW; Rider R; Glanville M; Narayanan K; Razvi S; Weaver JU
Cardiovasc Diabetol; 2016 Aug; 15(1):116. PubMed ID: 27561827
[TBL] [Abstract][Full Text] [Related]
9. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.
Matthews DR; Charbonnel BH; Hanefeld M; Brunetti P; Schernthaner G
Diabetes Metab Res Rev; 2005; 21(2):167-74. PubMed ID: 15386821
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
11. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
Jennings PE; Belch JJ
Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
[TBL] [Abstract][Full Text] [Related]
12. Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.
Vilar L; Canadas V; Arruda MJ; Arahata C; Agra R; Pontes L; Montenegro L; Vilar CF; Silva LM; Albuquerque JL; Gusmão A
Arq Bras Endocrinol Metabol; 2010 Mar; 54(3):311-8. PubMed ID: 20520962
[TBL] [Abstract][Full Text] [Related]
13. Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease.
Brunner S; Hoellerl F; Schmid-Kubista KE; Zeiler F; Schernthaner G; Binder S; Schernthaner GH
Invest Ophthalmol Vis Sci; 2011 Jun; 52(7):4655-62. PubMed ID: 21398276
[TBL] [Abstract][Full Text] [Related]
14. Antidiabetic effect of mangiferin in combination with oral hypoglycemic agents metformin and gliclazide.
Sekar V; Mani S; Malarvizhi R; Nithya P; Vasanthi HR
Phytomedicine; 2019 Jun; 59():152901. PubMed ID: 30981189
[TBL] [Abstract][Full Text] [Related]
15. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.
Ceriello A; Johns D; Widel M; Eckland DJ; Gilmore KJ; Tan MH
Diabetes Care; 2005 Feb; 28(2):266-72. PubMed ID: 15677777
[TBL] [Abstract][Full Text] [Related]
16. Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes.
Liao YF; Chen LL; Zeng TS; Li YM; Fan Yu ; Hu LJ; Ling Yue
Vasc Med; 2010 Aug; 15(4):279-85. PubMed ID: 20511292
[TBL] [Abstract][Full Text] [Related]
17. Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients.
Li F; Chen J; Leng F; Lu Z; Ling Y
Exp Clin Endocrinol Diabetes; 2017 Jun; 125(6):400-407. PubMed ID: 28407661
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation.
Khanolkar MP; Morris RH; Thomas AW; Bolusani H; Roberts AW; Geen J; Jackson SK; Evans LM
Atherosclerosis; 2008 Apr; 197(2):718-24. PubMed ID: 17765245
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus.
Wang CH; Ting MK; Verma S; Kuo LT; Yang NI; Hsieh IC; Wang SY; Hung A; Cherng WJ
Am Heart J; 2006 Dec; 152(6):1051.e1-8. PubMed ID: 17161050
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists.
Bahlmann FH; de Groot K; Mueller O; Hertel B; Haller H; Fliser D
Hypertension; 2005 Apr; 45(4):526-9. PubMed ID: 15767470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
